OBJECTIVE: Early initiation of low-dose aspirin (LDA) may reduce preeclampsia risk. We sought to determine whether LDA was beneficial when initiated <17w0d, within a trial of high-risk women enrolled <26w0d. STUDY DESIGN: Secondary analysis of the Maternal-Fetal Medicine Units High-Risk Aspirin study, including women enrolled <17w0d, randomized to LDA (60 mg day(-1)) or placebowith chronic hypertension (CHTN, n=186), diabetes (n=191) or prior preeclampsia (n=146). The primary outcome was preeclampsia at any time in pregnancy, secondary outcomes were early preeclampsia (<34w0d), late preeclampsia (⩾34w), small for gestational age (SGA; neonatal birthweight <10th %) and composite (early preeclampsia or SGA). Outcomes were compared by exact Χ(2)-tests. RESULTS: Baseline characteristics were similar between treatment groups. Aspirin was associated with a lower rate of late-onset preeclampsia ⩾34w (17.36% vs 24.42%, P=0.047), with a 41% reduction in women with CHTN (18.28% vs 31.18%, P=0.041). There were no other significant differences in the outcome. CONCLUSION:Aspirin initiated <17w0d reduced the risk for late-onset preeclampsia by 29% supporting the practice of early initiation of aspirin in high-risk women.
RCT Entities:
OBJECTIVE: Early initiation of low-dose aspirin (LDA) may reduce preeclampsia risk. We sought to determine whether LDA was beneficial when initiated <17w0d, within a trial of high-risk women enrolled <26w0d. STUDY DESIGN: Secondary analysis of the Maternal-Fetal Medicine Units High-Risk Aspirin study, including women enrolled <17w0d, randomized to LDA (60 mg day(-1)) or placebo with chronic hypertension (CHTN, n=186), diabetes (n=191) or prior preeclampsia (n=146). The primary outcome was preeclampsia at any time in pregnancy, secondary outcomes were early preeclampsia (<34w0d), late preeclampsia (⩾34w), small for gestational age (SGA; neonatal birthweight <10th %) and composite (early preeclampsia or SGA). Outcomes were compared by exact Χ(2)-tests. RESULTS: Baseline characteristics were similar between treatment groups. Aspirin was associated with a lower rate of late-onset preeclampsia ⩾34w (17.36% vs 24.42%, P=0.047), with a 41% reduction in women with CHTN (18.28% vs 31.18%, P=0.041). There were no other significant differences in the outcome. CONCLUSION:Aspirin initiated <17w0d reduced the risk for late-onset preeclampsia by 29% supporting the practice of early initiation of aspirin in high-risk women.
Authors: S Caritis; B Sibai; J Hauth; M D Lindheimer; M Klebanoff; E Thom; P VanDorsten; M Landon; R Paul; M Miodovnik; P Meis; G Thurnau Journal: N Engl J Med Date: 1998-03-12 Impact factor: 91.245
Authors: E Schiff; E Peleg; M Goldenberg; T Rosenthal; E Ruppin; M Tamarkin; G Barkai; G Ben-Baruch; I Yahal; J Blankstein Journal: N Engl J Med Date: 1989-08-10 Impact factor: 91.245
Authors: Yuval Bdolah; Chun Lam; Augustine Rajakumar; Venkatesha Shivalingappa; Walter Mutter; Benjamin P Sachs; Kee Hak Lim; Tali Bdolah-Abram; Franklin H Epstein; S Ananth Karumanchi Journal: Am J Obstet Gynecol Date: 2008-01-14 Impact factor: 8.661
Authors: Mary Catherine Tolcher; Derrick M Chu; Lisa M Hollier; Joan M Mastrobattista; Diana A Racusin; Susan M Ramin; Haleh Sangi-Haghpeykar; Kjersti M Aagaard Journal: Am J Obstet Gynecol Date: 2017-04-25 Impact factor: 8.661